Skip to main content
Clinical Trials/CTRI/2020/01/022785
CTRI/2020/01/022785
Not yet recruiting
Phase 2

An Open Label, Single Arm Clinical study To Evaluate The Safety and Efficacy of HPLT031707 SYRUP in Cases of Thrombocytopenia Associated With Dengue Fever in Pediatric Population - PL_S

The Himalaya Drug Company0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
The Himalaya Drug Company
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\)Both male and female pediatric subjects between the age group between \>\=2 years to \<\=12 years
  • 2\)Pediatric subjects already confirmed to have DF (Dengue Fever) through ELISA based NS1 Antigen test and/or IgM.
  • 3\)Pediatric subjects who have been clinically diagnosed with dengue fever associated with thrombocytopenia vis a vis platelet count between 50000 cells/mm3 to 1,00,000 cells/mm3\.
  • 4\)Pediatric subjects with the SGPT level not more than twice the upper limit of the normal
  • 5\)Parents/Guardians/Caregiver related to pediatric subject willing to give written informed consent for his/her participation to the study
  • 6\)Pediatric subject aged \> 7 years of age willing to sign the assent form for his/her participation in the study
  • 7\)Pediatric subjects who have not participated in this kind of trial in the past 4 weeks

Exclusion Criteria

  • 1\)Pediatric subjects diagnosed with DHF Grade 3 or 4,with hypotension / hypovolemia and dehydration
  • 2\)Pediatric subjects with platelet count \< 50000 cells/mm3
  • 3\)Pediatric subjects weighing \<10 Kgs and \>45 Kgs
  • 4\)Pediatric subjects with any febrile condition with temperature \>\=103 degree ofF and with a history of any febrile seizures.
  • 5\)Pediatric subjects presenting with hemorrhagic phenomena at Day 1 (screening/baseline) evidenced with petechiae, ecchymoses, or purpura, bleeding from the oral mucosa, gastrointestinal tract (hemetemesis or melaena.), injection sites or other locations.
  • 7\)Pediatric subjects with the history of juvenile diabetes mellitus treated with medication.
  • 8\)Pediatric subjects with the history of clinically significant cardiovascular condition treated with medication
  • 9\)Pediatric subjects with history of UTI or acute or chronic infectious condition and on any antibiotics like polymyxin B, rifampicin, amikacin, nalidixic acid, gentamycin, cholarmphenicol, oflaxacin
  • 10\)Pediatric subjects with a history of established hematological disorders including idiopathic thrombocytopenia purpura, leukemia, hemophilia
  • 11\)Pediatric subjects who have received blood products or blood/platelet transfusion during the current hospital stay or during last one month

Outcomes

Primary Outcomes

Not specified

Similar Trials